Back grey_arrow_rt.gif
 
Archived NATAP Articles from March 2003
 
null.gif
 
 
  1. Once Daily Valacyclovir Reduces Transmission of Genital Herpes - (3/31/03)

    2.  
  2. Retro - Assessment of the Multiple Dose Pharmacokinetic Interaction of Lopinavir/ritonavir with Nelfinavir (3/31/03)

    3.  
  3. Retro - Preliminary Study of Fosomax for Bone Mineral Loss in HIV (3/31/03)

    4.  
  4. Retro - Heart Disease in HIV: Retrovirus Report (3/28/03)

    5.  
  5. Deal Offers Novartis a Foothold in Hepatitis Viral Drugs NY Times By ALISON LANGLEY and ANDREW POLLACK March 27, 2003 - (3/28/03)

    6.  
  6. State AIDS Drug Programs Negotiate with Drug Manufacturers National Alliance of State and Territorial AIDS Directors Press Release 3/27/2003 - (3/28/03)

    7.  
  7. HIV Vaccine Candidates from Merck and Aventis Used Together Generate Encouraging Anti-HIV Immune Response in Monkeys - (3/28/03)

    8.  
  8. Emerging Reconstruction Procedures for HIV Facial Wastings By Nelson Vergel - (3/28/03)

    9.  
  9. EASL - OUTCOME OF LIVING DONOR LIVER TRANSPLANTATION (LDLT) : GRAFT SURVIVAL IS POOR ESPECIALLY IN HCV RECIPIENTS - (3/26/03)

    10.  
  10. EASL - A RANDOMISED DOUBLE-BLIND PHASE II STUDY OF LAMIVUDINE (LAM) COMPARED TO LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL (ADV) FOR TREATMENT NAIVE PATIENTS WITH CHRONIC HEPATITIS B (CHB) : WEEK 52 ANALYSIS - (3/26/03)

    11.  
  11. EASL - SIMVASTATIN AMMELIORATES THE INCREASED HEPATIC VASCULAR TONE IN PATIENTS WITH CIRRHOSIS - (3/26/03)

    12.  
  12. EASL - TENOFOVIR EFFECTIVELY INHIBITS VIRAL REPLICATION IN DIFFERENT PATIENT GROUPS WITH LAMIVUDINE RESISTANT HBV INFECTION - (3/26/03)

    13.  
  13. EASL - LIVER FIBROSIS REGRESSES BETTER WITH PEGINTERFERON ALPHA AND URSODEOXYCHOLIC ACID TREATMENT THAN SPONTANEOUS RECOVERY - (3/26/03)

    14.  
  14. EASL - EFFECT OF HBV AND HCV COINFECTION ON ANTI-VIRAL T CELL RESPONSES - (3/26/03)

    15.  
  15. EASL - A RANDOMIZED CONTROLLED TRIAL OF PEGYLATED-INTERFERON ALPHA-2B + RIBAVIRIN VS INTERFERON ALPHA-2B + RIBAVIRIN IN HIV CO-INFECTED PATIENTS - (3/26/03)

    16.  
  16. EASL - COMBINATION OF PEGYLATED INTERFERON AND LAMIVUDINE IS SUPERIOR TO LAMIVUDINE MONOTHERAPY IN THE TREATMENT OF CHRONIC HEPATITIS B - A RANDOMIZED TRIAL - (3/26/03)

    17.  
  17. EASL - PREDICTORS OF VIROLOGIC RESPONSE IN COMBINATION THERAPY WITH INTERFERON (IFN) ALFA 2B PLUS RIBAVIRIN OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION (LT) - (3/26/03)

    18.  
  18. EASL - PREDCTIVE FACTORS OF HCC RECURRENCE AFTER LIVER TRANSPLANTATION (OLT) : AN INTERIM ANALYSIS - (3/26/03)

    19.  
  19. EASL - Factors Associated With recurrence After Liver transplantation For Hepatocellular Carcinoma - (3/26/03)

    20.  
  20. EASL - A STUDY OF THE PRESENCE OF HCV RNA IN SEMEN OF PATIENTS WITH CHRONIC HCV INFECTION - (3/26/03)

    21.  
  21. HCV in Semen - (3/26/03)

    22.  
  22. EASL - EFFICACY OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN FOR 24 WEEKS IN GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C FOLLOWED BY MONO OR COMBINATION THERAPY FOR 22 WEEKS: PRELIMINARY ANALYSIS OF AN OPEN, MULTICENTER, RANDOMIZED TRIAL - (3/25/03)

    23.  
  23. EASL - Entecavir for HBV in Lamivudine Failures - (3/25/03)

    24.  
  24. EASL - EFFICIENCY OF DNA VACCINE IN ASSOCIATION WITH LAMIVUDINE FOR CHRONIC HEPATITIS B THERAPY - (3/25/03)

    25.  
  25. EASL - THE EFFECT OF PEGINTERFERON ALFA-2A (40 KD) ON LIVER HISTOLOGY IN CHRONIC HEPATITIS C: A META-ANALYSIS OF INDIVIDUAL PATIENTS DATA - (3/25/03)

    26.  
  26. EASL - Clevudine, New Drug for HBV - (3/25/03)

    27.  
  27. EASL - PHARMACOKINETICS OF PEGINTERFERON ALFA-2A (40KD, PEGASYS) COMPARED TO PEGINTERFERON ALFA-2B (12KD, PEGINTRON) IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C (CHC) - (3/25/03)

    28.  
  28. EASL - Study Suggests More Than 48 Weeks Therapy for Patients with high baseline viral loads, HCV genotype 1, and cirrhosis may be necessary - (3/25/03)

    29.  
  29. Fuzeon (T-20) Distribution Program and New T-20 Information - (3/20/03)

    30.  
  30. Retro - Cardiovascular Disease in HIV - Written by Carl J. Fichtenbaum, MD Associate Professor of Clinical Medicine University of Cincinnati College of Medicine(3/20/03)

    31.  
  31. Retro - Immune Reconstitution in Older HIV+ Individuals Written by David Margolis, MD, University of Texas, Southwestern Medical Center - (3/20/03)

    32.  
  32. Retro - RNA interference (RNAi): a recently discovered part of the machinery of the human cell, and a novel possibility for future therapy Written by David Margolis, MD, University of Texas, Southwestern Medical Center - (3/20/03)

    33.  
  33. FUZEON (T-20) Approved by the FDA - (3/17/03)

    34.  
  34. Night Before or After Pill To Prevent HIV Transmission - (3/17/03)

    35.  
  35. Retro - DAPD in 18 Treatment Experienced Patients - (3/17/03)

    36.  
  36. Retro - PRO 542: phase 1 study, drug administered by IV infusion - (3/17/03)

    37.  
  37. Retro - The Ongoing Story of Kaletra Resistance - (3/17/03)

    38.  
  38. Severe Hepatotoxicity During Combination Antiretroviral Treatment: Incidence, Liver Histology, and Outcome - (3/12/03)

    39.  
  39. Retro - Hepatitis C at Retrovirus Conference - (3/13/03)

    40.  
  40. Retro - Antiretroviral therapy: the main studies I Dr Graeme Moyle MD, MBBS, Chelsea and Westminster Hospital, London, UK. - (3/13/03)

    41.  
  41. Hepatitis C Virus in Patients With HIV Infection and Lipodystrophy - (3/12/03)

    42.  
  42. African Americans and their response to Hepatitis C Virus - (3/11/03)

    43.  
  43. Trizivir Compared to Efavirenz Plus Combivir: 48 weeks interim study results from ACTG 5095 - (3/11/03)

    44.  
  44. Gilead Sciences' Hepatitis B Drug Hepsera Approved for Marketing in European Union - (3/11/03)

    45.  
  45. Retro - Switch From Protease Inhibitor regimen to Once Daily Efavirenz Regimen Including FTC & ddI - (3/11/03)

    46.  
  46. Impaired Insulin Sensitivity in HIV-infected Individuals is Associated with Higher Hepatic Lipid Content and Visceral Adiposity - (3/10/03)

    47.  
  47. Retro - Incidence of Lipoatrophy and Lipohypertrophy in the Women's Interagency HIV Study - (3/10/03)

    48.  
  48. Retro - Fat and Bone: What D:A:D Says and Other Strangeness at CROI David Alain Wohl, MD - The University of North Carolina - (3/10/03)

    49.  
  49. Retro - Evidence Suggesting Mitochondrial Toxicity in HIV/HCV Co-infected Patients Receiving Ribavirin and Didanosine - (3/10/03)

    50.  
  50. Retro - TNX-355, anti-CD4 monoclonal antibody: Safety and preliminary Anti-HIV Activity - (3/10/03)

    51.  
  51. HIV+ Individuals Are Often Diagnosed Late in the Disease Stage - (3/7/03)

    52.  
  52. Retro - L-Carnitine Prevents Mitochondrial and Metabolic Disturbances Induced by Very High Dose of Stavudine in Mice - (3/7/03)

    53.  
  53. Retro - Niacin in HIV-infected Individuals with Hyperlipidemia Receiving Potent Antiretroviral Therapy: lipids improve, glucose measures may worsen - (3/7/03)

    54.  
  54. Resistance Testing Recommended For Pregnant Women: Nonnucleoside Reverse Transcriptase Inhibitor Resistance Observed Among Antiretroviral-Naive HIV-Positive Pregnant Women - (3/6/03)

    55.  
  55. Retro - Impact of Host Genetics on Clinical Outcomes Ronald Swanstrom, Ph.D. UNC Center For AIDS Research, University of North Carolina at Chapel Hill- (3/6/03)

    56.  
  56. Retro - Hepatitis C & B Report from Retrovirus Nancy Shulman, MD, Stanford University- (3/6/03)

    57.  
  57. Retro - Opportunustic Infections Report from Retrovirus Written for NATAP by David Margolis, MD, University of Texas Sothwestern Medical Center, VA Medical Cente - (3/6/03)

    58.  
  58. New HIV Drugs at Retrovirus 2003 Written by Mike Youle, MD, Royal Free Hospital, London, UK - (3/4/03)

    59.  
  59. Retro - Low-Dose Pegylated-Interferon in Early HIV to Reduce Viral Reservoir: pilot study - (3/4/03)

    60.  
  60. States Join Together to Press For Discounts on AIDS Drugs By LAURIE MCGINLEY Staff Reporter of THE WALL STREET JOURNAL - (3/3/03)

    61.  
  61. Retro - Entry Inhibitors, The How and Why of New Agents at Retrovirus: an Update Reported by Christopher D. Pilcher, M.D. UNC at Chapel Hill Center for AIDS Research - (3/3/03)

    62.  
  62. Retro - The New AIDS Fight: A Plan as Simple as ABC - (3/3/03)

    63.  
  63. The 2NN Study: a comparison between efavirenz and nevirapine By Dr Graeme Moyle MD, MBBS, Chelsea & Westminster Hospital, London, UK - (3/3/03)

    64.  
  64. Retro - STI and immunology summary CROI Mark Dybul, MD National Institute of Health - (3/3/03)

    65.  
  65. Retro - HAART REDUCES DEATH AMONG HOMELESS - (3/3/03)

    66.